BioSpace News Archive

Cullinan Oncology, LLC announced today the appointment of Jeffrey Trigilio as the company’s Chief Financial Officer. In addition to his primary financial responsibilities, Jeff will play an important role across many facets of the business, including business development, project management and investor relations. “We are fortunate to have someone of Jeff’s caliber join Cullinan at this stage of the company’s devel

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter 2020 on Tuesday, November 17, 2020. The Company has scheduled a conference call for that same day, Tuesday, November 17, 2020 at 11:00am ET (4:00pm GMT) to discuss the results of the quarter. Interested parties can access the call by dialing: US Tol

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease

WUHAN GENERAL GROUP, INC., a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update

AzurRx BioPharma, Inc. ( NASDAQ: AZRX ) (“AzurRx” or the “Company”), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, today provides insight on the usage of porcine products in producing pharmaceuticals and medicinals and the inherent downsides associated with this usage, as well as updates regarding its own

Innovative scientific research results on Coronavirus disease (COVID-19) and its impact on obesity will be presented through oral and poster abstracts at the 38th Annual Meeting of The Obesity Society (TOS) at ObesityWeek® Interactive

Seqirus, a global leader in influenza prevention, today presented absolute efficacy data on the company’s cell-based quadrivalent influenza vaccine (QIVc) from a randomized controlled trial (RCT) which met its primary endpoint in children and adolescents between ≥2 to <18 years of age over three influenza seasons. 1 This study, w

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

--Integrating 3D genomics with publicly available, genome-wide genetic data, researchers uncovered genetic correlations between IBD, stress, and depression--

- First results from the Phase 3 BE SURE study will be presented showing superior skin clearance with bimekizumab compared to Humira® (adalimumab) in patients with moderate-to-severe plaque psoriasis - Two oral presentations from the Phase 3 BE VIVID study show consistent levels of skin clearance with bimekizumab irrespective of patient demographics, disease characteristics and prior treatment experience, and an acceptable safety profile based on an integrated analysis across Phase 2 a